Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity

Abstract

To explore the expression of Beclin1 in osteosarcoma and investigate the effects of down-regulation of autophagy on the chemotherapeutic sensitivity to cisplatin (DDP), the expression of Beclin1 in 28 specimens of osteosarcoma (group A) and 19 specimens of normal bone tissues (group B) were immunohistochemically detected. The expression of Beclin1 mRNA in MG63 cells treated with different concentrations of DDP was examined with RT-PCR. After down-regulation of autophagy in MG63 cells by an autophagy inhibitor, 3-methyladenine (3-MA), the cell proliferation inhibition rate of MG63 cells treated with DDP was evaluated by using the MTT assay. The positive rates of Beclin1 were 67.85% in group A and 94.73% in group B. Its expression was lower in osteosarcoma than in normal bone tissues, with a significant difference found between them (P<0.05). RT-PCR showed that the expression of Beclin1 mRNA in the cells treated with high-dose DDP were higher than that in the non-treated cells, and no significant difference in the expression of Beclin1 mRNA was found between the cells treated with low-dose DDP and the non-treated cells. There was a positive correlation between the level of Beclin1 mRNA expression and the concentration of DDP. MTT assay showed that the proliferation inhibition rates of the cell treated with 3-MA and DDP combined were substantially increased when compared with those treated with DDP alone (P<0.01). This study demonstrated that autophagy may be implicated in the carcinogenesis of osteosarcoma, and DDP may induce autophagy in the MG63 cells. It also suggests that the down-regulated autophagy could increase chemotherapeutic sensitivity of DDP to osteosarcoma.

Keywords

Beclin1 / osteosarcoma / autophagy / 3-methyladenine / cisplatin

References

[1] DassC.R., ChoongP.F.. Gene therapy for osteosarcoma: steps towards clinical studies. J Pharm Pharmacol, 2008, 60(4): 405-413

[2] EnomotoM., HayakawaS., ItsukushimaS., et al.. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene, 2009, 28(36): 3197-3208

[3] MeyerR., FofanovV., PanigrahiA., et al.. Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers. Clin Caner Res, 2009, 15(80): 2703-2710

[4] JohnS., NayveltI., HsuH.C., et al.. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res, 2008, 68(19): 7855-7863

[5] LiangX.H., JacksonS., SeamanM., et al.. Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature, 1999, 402(6762): 672-676

[6] KatayamaM., KawaguchiT., BergerM.S., et al.. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ, 2007, 14(3): 548-558

[7] TafaniM., SchitoL., AnwarT., et al.. Induction of autophagic cell death by a noval molecule is increased by hypoxia. Autophagy, 2008, 4(8): 1042-1053

[8] SalvensenH.B., StefanssonI., KalvenesM.B., et al.. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer, 2002, 94(8): 2185-2191

[9] BacciG., LonghiA., FagioliF., et al.. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer, 2005, 41(18): 2836-2845

[10] CheonG.J., KimM.S., LeeJ.A., et al.. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med, 2009, 50(9): 1435-1440

[11] IwamotoY., TanakaK., IsuK., et al.. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci, 2009, 14(4): 397-404

[12] CarrleD., BielackS.S.. Current strategies of chemotherapy in osteosarcoma. Int Orthop, 2006, 30(6): 445-451

[13] ChiantoreM.V., VannucchiS., ManginoG., et al.. Senescence and cell death pathways and their role in cancer therapeutic outcome. Curr Med Chem, 2009, 16(3): 287-300

[14] CheungZ.H., IpN.Y.. The emerging role of autophagy in Parkinson’s disease. Mol Brain, 2009, 2(1): 29

[15] ChaturvediA., PierceS.K.. Autophagy in immune cell regulation and dysregulation. Curr Allergy Asthma Rep, 2009, 9(5): 341-346

[16] CaoY., KlionskyD.J.. Physiologic functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res, 2007, 17(10): 839-849

[17] QuX., YuJ., BhagatG., et al.. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest, 2003, 112(12): 1809-1820

[18] ScarlattiE., BauvyC., VentrutiA., et al.. Ceramide-mediated macroautophagy involves inhibits of protein kinase B and up-regulation of beclin 1. J Biol Chem, 2004, 279(18): 18384-18391

[19] YueZ., JinS., YangC., et al.. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA, 2003, 100(25): 15077-15082

[20] TsujimotoY., ShimizuS.. Another way to die: autophagic programmed cell death. Cell Death Differ, 2005, 12(Suppl2): 1528-1534

[21] RavikumarB., BergerZ., VacherC., et al.. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet, 2006, 15(7): 1209-1216

[22] ShimizuS., KanasekiT., MizushimaN., et al.. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol, 2004, 6(12): 1221-1228

[23] LambertL.A., QiaoN., HuntK.K., et al.. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res, 2008, 68(19): 7966-7974

[24] KlionskyD.J.. The molecular machinery of autophagy: unanswered questions. J Cell Sci, 2005, 118(pt1): 7-18

[25] SunQ., FanW., ChenK., et al.. Identification of Barkor as a mammalian autophagy-specific factor for Beclin1 and class III phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA, 2008, 105(49): 19211-19216